Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02915601 · ClinicalTrials.gov registry record · NA

Bicarbonate Administration in CKD

A NA study, sponsored by University of Colorado, Denver.

Completed
Registry status
NA
Development phase
109
Enrollment target

NCT02915601 is a NA study that has completed, run by University of Colorado, Denver. The registered enrollment target is 109 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02915601, a NA study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
NA
Development phase
109 participants
Enrollment target

Study Summary

Low serum bicarbonate levels, even within the normal laboratory range, are strongly associated with increased risks of hypertension, endothelial dysfunction, cardiovascular disease and death. The current proposal will investigate whether bicarbonate administration in patients with chronic kidney disease (CKD) will improve the health and function of arteries and reduce the size of the left ventricle of the heart. Overall, the proposed research will provide important new scientific evidence upon which physicians can base recommendations to patients with CKD to decrease the risk of developing cardiovascular diseases.

Interventions

  • DRUG Placebo
  • DRUG Sodium bicarbonate

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2017-01-15
Est. Completion 2022-05-19
Phase NA

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02915601

The ClinicalTrials.gov registry entry for NCT02915601 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02915601 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02915601 about?

NCT02915601 is a clinical study titled "Bicarbonate Administration in CKD". Low serum bicarbonate levels, even within the normal laboratory range, are strongly associated with increased risks of hypertension, endothelial dysfunction, cardiovascular disease and death. The current proposal will investigate whether bicarbonate administration in patients with chronic kidney dis...

What is the current status of trial NCT02915601?

This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2017-01-15. Estimated completion is 2022-05-19.

What interventions are being tested in trial NCT02915601?

The interventions under investigation include: Placebo (DRUG), Sodium bicarbonate (DRUG).

Who is sponsoring clinical trial NCT02915601?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.